Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures
- PMID: 11751595
- DOI: 10.1210/endo.143.1.8580
Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures
Abstract
Using primary murine bone marrow cell cultures, we demonstrate that inhibin suppresses osteoblastogenesis and osteoclastogenesis. In contrast, activin supports osteoblast formation (by alkaline phosphatase-positive and mineralized colony formation); and activin also stimulates osteoclast formation (as measured by staining tartrate-resistant acid phosphatase-positive multinucleated cells). Inhibin, the activin antagonist follistatin, and the bone morphogenetic protein antagonist noggin can all suppress endogenous activin accumulation in bone marrow cultures. Associated with this decrease in activin is the loss of mineralized osteoblastic colony formation (colony forming unit-osteoblast; CFU-OB). However, exogenous activin administration, even in the presence of noggin, permits both alkaline phosphatase-positive and CFU-OB colony formation in vitro. In contrast, the stimulatory effects of locally produced activin on osteoblast and osteoclast development are not likely to be dominant over the suppressive effects of gonadally derived inhibin. The suppressive effect of inhibin is maintained in the presence of either activin or bone morphogenetic protein, suggesting the presence of a distinct inhibin-specific receptor. Taken together, the direct regulation of osteoblastogenesis and osteoclastogenesis by inhibin and activin in vitro suggest that changes in the inhibin/activin ratio detected by bone marrow cells, during the perimenopausal transition, contribute to altered cell differentiation and may be associated with the increased bone resorption observed at this time.
Similar articles
-
Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.Mol Cell Endocrinol. 2009 Oct 30;310(1-2):11-20. doi: 10.1016/j.mce.2009.07.001. Epub 2009 Jul 15. Mol Cell Endocrinol. 2009. PMID: 19615428 Free PMC article. Review.
-
Role of TGF-beta family in osteoclastogenesis induced by RANKL.Cell Signal. 2002 Jan;14(1):31-6. doi: 10.1016/s0898-6568(01)00221-2. Cell Signal. 2002. PMID: 11747986
-
Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin.J Bone Miner Res. 2000 Apr;15(4):663-73. doi: 10.1359/jbmr.2000.15.4.663. J Bone Miner Res. 2000. PMID: 10780858
-
Follistatin restricts bone morphogenetic protein (BMP)-2 action on the differentiation of osteoblasts in fetal rat mandibular cells.J Bone Miner Res. 2004 Aug;19(8):1302-7. doi: 10.1359/JBMR.040408. Epub 2004 May 3. J Bone Miner Res. 2004. PMID: 15231018
-
The contribution of inhibins and activins to malignant prostate disease.Mol Cell Endocrinol. 2001 Jun 30;180(1-2):149-53. doi: 10.1016/s0303-7207(01)00497-x. Mol Cell Endocrinol. 2001. PMID: 11451585 Review.
Cited by
-
Low bone mass and impaired fracture healing in mouse models of Trisomy21 (Down syndrome).Bone. 2022 Sep;162:116471. doi: 10.1016/j.bone.2022.116471. Epub 2022 Jun 15. Bone. 2022. PMID: 35716916 Free PMC article.
-
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.PLoS One. 2009;4(4):e5275. doi: 10.1371/journal.pone.0005275. Epub 2008 Apr 16. PLoS One. 2009. PMID: 19357790 Free PMC article.
-
Update in new anabolic therapies for osteoporosis.J Clin Endocrinol Metab. 2010 Apr;95(4):1496-504. doi: 10.1210/jc.2009-2677. J Clin Endocrinol Metab. 2010. PMID: 20375217 Free PMC article. Review.
-
GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone.Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4910-4920. doi: 10.1073/pnas.1916034117. Epub 2020 Feb 18. Proc Natl Acad Sci U S A. 2020. PMID: 32071240 Free PMC article.
-
A novel osteoporosis model with ascorbic acid deficiency in Akr1A1 gene knockout mice.Oncotarget. 2017 Jan 31;8(5):7357-7369. doi: 10.18632/oncotarget.14458. Oncotarget. 2017. PMID: 28060768 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous